Fig. 1

The expression level of SYTL2 is correlated with metastasis and poor prognosis in PCa patients. A Venn diagram shows the intersecting genes with high expression in PCa among the CPGEA database (primary PCa vs adjacent nontumor samples, logFC > 1.2, p < 0.05) and two GEO datasets, GSE45016 (mPCa vs localized PCa) and GSE67872 (mPCa vs normal, logFC > 1.2, p < 0.05). B, C Kaplan‒Meier curves for DFS (B) and BCR-free survival (C) of PCa patients with high versus low expression of SYTL2 in TCGA. D The expression of SYTL2 in GSE67872 compared among normal, localized PCa and mPCa samples. E The expression of SYTL2 in CPGEA that compared Gleason scores 6–7 (3 + 4) with Gleason scores 7 (4 + 3) − 10. F Representative images of SYTL2 expression in mPCa tissues and localized PCa tissues. G–I The expression of SYTL2 in the FFPE-SYSCC cohort that compared nonmPCa with mPCa (G), nonlymph node metastatic tissue with lymph node metastatic tissue (H) and Gleason scores 6–7 (3 + 4) with Gleason scores 7 (4 + 3) − 10 (I). J–L Kaplan‒Meier curves for DFS (J), BCR-free survival (K) and OS (L) of PCa patients with high versus low expression of SYTL2 in the FFPE-SYSCC cohort. *p < 0.05, **p < 0.01 and ***p < 0.001, ns no significant, Scale bars: 250 μm (black); 50 μm (red)